{"Symbol": "EVOK", "AssetType": "Common Stock", "Name": "Evoke Pharma, Inc", "Description": "Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. The company was founded in 2007 and is headquartered in Solana Beach, California.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Drug ManufacturersSpecialty & Generic", "Address": "420 Stevens Avenue, Solana Beach, CA, United States, 92075", "FullTimeEmployees": "5", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "114449720", "EBITDA": "None", "PERatio": "None", "PEGRatio": "-0.1", "BookValue": "0.119", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.395", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.9293", "ReturnOnEquityTTM": "-3.9528", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.482", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "9.5", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "34.6656", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "2.033", "52WeekHigh": "6.063", "52WeekLow": "0.7332", "50DayMovingAverage": "4.2735", "200DayMovingAverage": "2.4273", "SharesOutstanding": "26011300", "SharesFloat": "22948957", "SharesShort": "1216361", "SharesShortPriorMonth": "309720", "ShortRatio": "1.2", "ShortPercentOutstanding": "0.03", "ShortPercentFloat": "0.0275", "PercentInsiders": "4.149", "PercentInstitutions": "14.522", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}